A method for treating an influenza virus infection is described. The disclosed method generally involves administering an effective amount of a compound, for example baloxavir marboxil, to a subject having an influenza virus infection and at least one complication risk factor. Generally, the amount is effective such that a reduction in a time to improvement of at leat one symptom of an influenza virus infection is statistically significant as compared to that of a non-treated subject.

The present invention discloses a number of polycyclic amines that are useful as opioid receptor modulators. The compounds of the invention are useful in both therapeutic and diagnostic methods, including for treating pain, neurological disorders, cardiac disorders, bowel disorders, drug and alcohol addiction, drug overdose, urinary disorders, respiratory disorders, sexual dysfunction, psoriasis, graft rejection or cancer.

The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.

The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.

The invention relates to a combination of Diltiazem and at least one viral polymerase inhibitor compound selected from among Baloxavir marboxil, Pimodivir, RO-7 and CC-42344. The invention relates in particular to the therapeutic use of said combination in the prevention and/or treatment of a viral infection, in particular of the respiratory and/or intestinal tract of a human or animal body.

The invention relates to a combination of Diltiazem and at least one viral polymerase inhibitor compound selected from among Baloxavir marboxil, Pimodivir, RO-7 and CC-42344. The invention relates in particular to the therapeutic use of said combination in the prevention and/or treatment of a viral infection, in particular of the respiratory and/or intestinal tract of a human or animal body.

The invention relates to a combination of Diltiazem and at least one viral polymerase inhibitor compound selected from among Baloxavir marboxil, Pimodivir, RO-7 and CC-42344. The invention relates in particular to the therapeutic use of said combination in the prevention and/or treatment of a viral infection, in particular of the respiratory and/or intestinal tract of a human or animal body.

Devices, systems and methods for localized delivery of a chemotherapy, hormonal therapy or targeted drug/biologic therapy to a target tissue area of an internal body organ of a patient. A catheter forms a sealed treatment chamber in a natural lumen extending through the target tissue area. Air is purged from the chamber, which is then filled with a liquid drug solution for an adequate treatment session time, solution volume and drug concentration to saturate the target tissue area, thereby providing the treatment. The drug concentration in the liquid soaking solution may be formulated to approximate the known maximum plasma concentration achieved during systemic delivery of the same drug. An integrated pressure relief circuit may be included to avoid unsafe pressure levels in the isolated chamber. The chamber is evacuated at the end of the treatment session.

Devices, systems and methods for localized delivery of a chemotherapy, hormonal therapy or targeted drug/biologic therapy to a target tissue area of an internal body organ of a patient. A catheter forms a sealed treatment chamber in a natural lumen extending through the target tissue area. Air is purged from the chamber, which is then filled with a liquid drug solution for an adequate treatment session time, solution volume and drug concentration to saturate the target tissue area, thereby providing the treatment. The drug concentration in the liquid soaking solution may be formulated to approximate the known maximum plasma concentration achieved during systemic delivery of the same drug. An integrated pressure relief circuit may be included to avoid unsafe pressure levels in the isolated chamber. The chamber is evacuated at the end of the treatment session.

The present embodiments relate to a method of treating dry eyes. The method includes a plurality of visits to an eye doctor with each even numbered visit focused on a first eye and each odd numbered visit focused on a second eye. The plurality of visits comprises use of intense pulsed light (“IPL”) therapy, low level light therapy, an ocular nebulizer, dehydrated amniotic membranes, biologic eye drops, advanced lubricants, eyelid debridement, meibomian gland imaging and a slit lamp.